Skip to content
10-Q

Quarterly Report

Spero Therapeutics, Inc. SPRO

0001193125-26-221591

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 57.9M sh
Shares Diluted Q1 2026 · Mar 31, 2026 57.28M sh
Shares Diluted Q1 2026 · Mar 31, 2025 55.38M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 $15.86M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $56.13M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $40.27M
Stockholders Equity Q1 2026 · Mar 31, 2026 $52.93M
Stockholders Equity Q1 2026 · Dec 31, 2025 $59.02M
Stockholders Equity Q1 2026 · Mar 31, 2025 $33.81M
Stockholders Equity Q1 2026 · Dec 31, 2024 $46.12M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.49M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.87M
Total Liabilities Q1 2026 · Mar 31, 2026 $6.09M
Total Liabilities Q1 2026 · Dec 31, 2025 $9.9M
Current Assets Q1 2026 · Mar 31, 2026 $57.61M
Current Assets Q1 2026 · Dec 31, 2025 $67.29M
Total Assets Q1 2026 · Mar 31, 2026 $59.02M
Total Assets Q1 2026 · Dec 31, 2025 $68.92M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.13
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.25
Eps Basic Q1 2026 · Mar 31, 2026 −$0.13
Eps Basic Q1 2026 · Mar 31, 2025 −$0.25
Sga Expense Q1 2026 · Mar 31, 2026 $4.89M
Sga Expense Q1 2026 · Mar 31, 2025 $6.82M
Rd Expense Q1 2026 · Mar 31, 2026 $2.91M
Rd Expense Q1 2026 · Mar 31, 2025 $13.61M
Net Income Q1 2026 · Mar 31, 2026 −$7.2M
Net Income Q1 2026 · Mar 31, 2025 −$13.87M
Operating Income Q1 2026 · Mar 31, 2026 −$7.54M
Operating Income Q1 2026 · Mar 31, 2025 −$14.73M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $12K